The Cost Impact of Cytomegalovirus Disease in Renal Transplant Recipients

Jm, McCarthy; Ma, Ketao; Krueger, Heike; Pa, Keown

doi:10.1097/00007890-199306000-00013

Cited by 79 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 CMV disease also results in prolonged hospitalization and considerably impacts on the cost of OLT. 15 It has been estimated that CMV disease can add 40% to the cost of transplantation, 16 and it has been shown recently that its prophylaxis can be cost-effective. 17 …”

Section: Clinical Spectrum Of CMV Infection After Oltmentioning

confidence: 99%

Management of cytomegalovirus infection after liver transplantation

Sampathkumar

Payá

2000

Liver Transpl

View full text Add to dashboard Cite

Section: Clinical Spectrum Of CMV Infection After Oltmentioning

confidence: 99%

Management of cytomegalovirus infection after liver transplantation

Sampathkumar

Payá

2000

Liver Transpl

View full text Add to dashboard Cite

“…In renal transplant recipients, CMV disease is associated not only with considerable morbidity and mortality, but also with increased risk of acute rejection, interstitial fibrosis and tubular atrophy or chronic rejection, and finally impaired long-term graft and patient survival [2,3,4,5,6,7,8]. Direct and indirect effects of CMV infection are accompanied by increased hospital stay and excessive costs [9,10]. …”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic Impact of Different Regimens to Prevent Cytomegalovirus Infection in Renal Transplant Recipients

Kielberger¹,

Bouda²,

Jindra³

et al. 2012

Kidney Blood Press Res

View full text Add to dashboard Cite

Background: The aim of this study was to determine the cost impact of four different strategies for prevention of cytomegalovirus (CMV) disease after renal transplantation. Methods: Hospitalization data and medical resource utilization data were prospectively collected alongside two randomized trials. In the first trial, the patients were randomized to 3-month prophylaxis with either oral ganciclovir (1 g t.i.d., n = 36) or valacyclovir (2 g q.i.d., n = 35), and to the control group (n = 12) managed by deferred therapy. In the second trial, the patients were randomly assigned to 3-month valacyclovir prophylaxis (n = 34) or preemptive therapy with valganciclovir (900 mg b.i.d. for a minimum of 14 days, n = 36) for significant CMV DNAemia. The cost analysis involved all real costs directly related to CMV during the first year after renal transplantation. Results: The mean CMV-associated costs per patient were EUR 4,581, 2,577, 4,968, and 8,050 in patients in the ganciclovir, valacyclovir, preemptive, and deferred therapy groups, respectively (p < 0.001). Valacyclovir prophylaxis was significantly less expensive than any other regimen. The cost of one episode of CMV disease was EUR 7,510 per patient. Due to excessive incidence of CMV disease, deferred therapy was the most expensive strategy (p < 0.001). Conclusions: Valacyclovir prophylaxis is less expensive strategy compared with any other regimen.

show abstract

“…Important risk factors for developing CMV disease include retransplantation and the use of lymphocyte-depleting antibodies for immunosuppression (6). Cytomegalovirus infection increases the risk of rejection and predisposes the immunosuppressed recipient to opportunistic infections (9), which ultimately increase hospitalization and cost (10).…”

Section: Introductionmentioning

confidence: 99%

Cytomegalovirus Prevalence and Transmission After Islet Allograft Transplant in Patients with Type 1 Diabetes Mellitus

Hafiz¹,

Poggioli²,

Caulfield³

et al. 2004

American Journal of Transplantation

View full text Add to dashboard Cite

Cytomegalovirus (CMV) serological status of transplant donors and recipients has important implications on antiviral prophylaxis, morbidity/mortality, donor selection and hospital stay. We evaluated CMV prevalence in our islet transplant candidates (ITC) in comparison with organ donors. We correlated the CMV serological status of our ITC with serology for Epstein-Barr virus and Parvovirus B19, auto-antibodies, patient's age, age at DM onset, duration of DM, gender, race, ABO group, HLA haplotype and C-peptide levels. Cytomegalovirus transmission after islet transplant using the Edmonton regimen was also evaluated. Cytomegalovirus seropositivity varied according to patient group, age, gender and race. Type 1 DM patients had reduced odds of CMV seropositivity when compared with organ donors. In all groups studied, older patients, females, and non-Caucasians were more likely to be CMV seropositive. In addition, no CMV reactivation, infection or disease was observed among our transplanted patients using this steroid-free regimen even after donor/recipient CMV mismatch.

show abstract

The Cost Impact of Cytomegalovirus Disease in Renal Transplant Recipients

Cited by 79 publications

References 0 publications

Management of cytomegalovirus infection after liver transplantation

Management of cytomegalovirus infection after liver transplantation

Pharmacoeconomic Impact of Different Regimens to Prevent Cytomegalovirus Infection in Renal Transplant Recipients

Cytomegalovirus Prevalence and Transmission After Islet Allograft Transplant in Patients with Type 1 Diabetes Mellitus

Contact Info

Product

Resources

About